Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

http://www.wikidata.org/entity/Q41530079

about

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Molecular targeting in acute myeloid leukemia Emerging therapies for acute myeloid leukemia: translating biology into the clinic.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.Progress and criticalities in the management of acute promyelocytic leukemia.A concise review of BCL-2 inhibition in acute myeloid leukemia.Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.The rocky road to personalized medicine in acute myeloid leukaemia.Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Wild-type and mutated IDH1/2 enzymes and therapy responses.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.Advances in targeted therapy for acute myeloid leukaemia.Genomics in childhood acute myeloid leukemia comes of age.Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.First metabolic oncology inhibitor gets FDA green light, with record price tag.Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment.Enasidenib: First Global Approval.Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma.A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia.Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

P2860

38df6ff7a0d7117a63806821f24f144dbf6fbb78

P248

Q38674045-588EFEF6-073C-4654-8995-39F80C0A0A35 Q41558732-F5A56663-9B1D-4768-8F51-BD7C65B3F600 Q41984963-BE8BE094-829C-4048-92AF-0B49B3C396EE Q47136441-C600C2F7-05BE-46FF-B22C-C6BC92532A52 Q47140333-3E47429C-9882-40ED-BEB0-052F6ED2CBCE Q47160338-CE0DFD15-B053-4E55-AB89-7DF8D4D09587 Q47271349-3E4BEEDC-7B0D-4535-9FC2-8877D2422C2C Q47290687-92EB167C-DCCB-4FA3-9713-C6169EEB02E9 Q47339574-23BC933D-0DDA-4768-908C-CF96A939BA15 Q47548041-67F26A08-296A-4F73-AC2D-FE1A5292A002 Q47561008-D575E317-226C-42EE-81FF-802BDF9EA51F Q47561019-9FB370B1-981A-47BA-A8FC-E8EB539FB695 Q47579728-6DE15842-C324-4604-B89C-E890474EF34E Q47605895-A0B2DC95-6B3D-4F91-B9ED-71D12FAC1DFD Q47713415-A3CB552E-D626-4F1A-927F-3549E24B93BE Q47741553-661DD50B-2B09-49CC-8068-95970C568CF4 Q48154329-655CF16A-11AA-4681-8CBA-8317FBA8B1AC Q48155332-35B8F7E4-2F5A-4AC0-8411-89136854CB24 Q48204144-8F4CDC09-2ABE-4D82-8BE2-456ECE94AE55 Q48284209-DB8AA4B7-0412-43B6-93FC-F61221632397 Q48533330-3CC1CE39-D9B0-4AA7-B379-F526F4396BA5 Q48592284-DFB2086D-B96A-47BF-80B8-AEF7AE161865 Q48595265-F10043CB-7BE4-4EDA-81D6-1D6C4C90547D Q49833698-CE80FDF3-7186-45B6-B03B-37434D6F500D Q49976405-A7B79D63-1187-4A2C-B29F-B340735FC73F Q50093979-7E2E9897-2C8A-488D-AF08-6EC782D1B86D Q50097999-58185CDB-DA3C-4196-BEAF-9FF87A4D815F Q50209891-C4AC8731-9419-4175-A936-71719553A1B6 Q51773142-0FC379E6-FE33-481D-86BB-9DEE4A9BF7D1 Q52579090-B4925D97-C538-4DC3-A2BE-32B15585AD8F Q52629240-5D710BC7-74B5-4C5A-BA77-AA186BE2C8ED Q52641884-88E4F021-4EC4-4396-BDEC-8E47FF44C5FD Q54956859-00C12DE6-34AC-4882-B042-1148069135CB Q55038084-B2B0995A-FE6C-4D8E-89E5-3503A0BE167F Q55433291-01264E14-0B52-4054-B845-9587881B71FC Q55456962-D67C8117-2F51-40B2-A6DD-0FB83C22E583 Q55472969-79EA4AB6-BC2F-41E1-A6BB-2D0D20F9D437 Q55515367-3831E167-1998-42CD-9B03-092F6DE3D0D3 Q55515402-CE702A1C-34F6-4D82-A116-71D7DF8C9AFE Q55515597-9C22F356-A3B2-4227-B5AB-1C15ABAA3FE1

P2860

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

http://www.wikidata.org/entity/Q41530079

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

@en

type

label

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

@en

prefLabel

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

@en

P1433

Q41530079-24E27091-6750-493B-A8D9-ED56C274E602

P1476

Q41530079-F55C2367-0CC5-4742-9DE9-DE94845682D6

P2093

Q41530079-01B63EAD-E1FB-4E34-90D2-084421FE25D9

Q41530079-4F6A1079-D6E3-4D67-9F16-2D29692A351F

Q41530079-521E2397-6C6C-482A-936C-1028E053330B

Q41530079-5DC135B3-7B6B-4F59-B985-4295BC8B4087

Q41530079-5DFB0D4E-9ACB-40ED-A968-009EDFF94B32

Q41530079-5F38D77F-5417-4C5F-9D5C-57172FDC1774

Q41530079-637C175D-C5A2-4D4C-8E33-A1F06ADF75EB

Q41530079-7088E12B-49FA-4139-9EBB-943BCFE7E08C

Q41530079-7E9366F0-D65C-46D5-9BA0-A096A8958923

Q41530079-8141C091-9227-4570-AE8A-5E89B1C0E88F

P2860

Q41530079-021704A1-07E1-427B-8EAC-876D0287C788

Q41530079-0786165F-3041-4B59-BAF1-B93BCF51CFFD

Q41530079-0CAE368B-A4B2-40E7-AFEC-B398848D1F65

Q41530079-0EB66225-9432-4B0F-B849-4915328B1FB5

Q41530079-1634FA36-C983-4710-91F7-B72E649A861C

Q41530079-18B8569A-4BF1-4250-BE94-CEB80364ADFC

Q41530079-2BEA1557-5D52-43E7-8780-C055F36EE8C7

Q41530079-2FFF4858-034B-4CFB-8C85-C2C17265B92F

Q41530079-3135F9DD-E9A2-47F9-BE70-26516D4C013D

Q41530079-317ADE4B-CB7F-42D6-BCD2-DB6F66474961

P304

Q41530079-884BF5F9-7F6B-4E2C-A632-F7E7E677DDDA

P31

Q41530079-C2E300D7-4E54-41F8-9646-858AE758E41B

P356

Q41530079-D24177CE-4877-47EC-BBBE-E4A39BD50001

P407

Q41530079-016F3809-F7B8-4DD1-89EB-01690500B622

P433

Q41530079-B2C759A4-5F6D-48DE-BAED-DB8B4D0D9A23

P478

Q41530079-57FFF742-2EBF-4B49-AAED-B8020771E32F

P50

Q41530079-30CE1FF6-1B6F-4B6D-9B7B-CFE7B26C16F4

Q41530079-4B3E7FD8-7005-4C4B-827B-A222CACE94A5

Q41530079-5AF34691-94E5-4577-9CB4-CCAD21B2F3BB

Q41530079-A5C57CE9-CB7C-4884-8B87-2E6A9718419B

Q41530079-A6142398-4A9A-4B70-A196-B12525B45DC2

Q41530079-EBBE1CE3-295D-4B97-9770-AD57C5A24811

Q41530079-F6092DAC-E9A4-455C-BE41-205DB9982620

P577

Q41530079-134FFB84-A2D2-43D6-8C5E-B3B1934A2C38

P698

Q41530079-6BE6F758-A68A-4B16-8E83-1168EAAD2212

P921

Q41530079-BF063605-1626-423A-8FC6-1AB346768CF3

P932

Q41530079-6558942C-8277-48F8-8AA9-4CFC6B4C8DF7

P356

BLOOD-2017-04-779405

P1433

P1476

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

@en

P2093

Alessandra Tosolini

http://www.w3.org/2001/XMLSchema#string

Amir T Fathi

http://www.w3.org/2001/XMLSchema#string

Anthony Stein

http://www.w3.org/2001/XMLSchema#string

Bruno C Medeiros

http://www.w3.org/2001/XMLSchema#string

Courtney D DiNardo

http://www.w3.org/2001/XMLSchema#string

Daniel A Pollyea

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Eytan M Stein

http://www.w3.org/2001/XMLSchema#string

Gail J Roboz

http://www.w3.org/2001/XMLSchema#string

Jessica K Altman

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

All-trans-retinoic acid in acute promyelocytic leukemia

Acute Myeloid Leukemia

IDH mutation impairs histone demethylation and results in a block to cell differentiation

P304

722-731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2017-04-779405

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane de Botton

Hagop Kantarjian

Arthur E. Frankel

Martin S Tallman

P577

2017-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28588020

http://www.w3.org/2001/XMLSchema#string

P921

P932

5572791

http://www.w3.org/2001/XMLSchema#string